Esophageal Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 80+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Esophageal Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:
• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.
• Esophageal Cancer companies working in the treatment market are , and others, are developing therapies for the Esophageal Cancer treatment
• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- , and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.
• In September 2022, Daiichi Sankyo and Sarah Cannon Research Institute (SCRI) presented updated findings from a phase I/II trial of DS-7300, demonstrating sustained and encouraging tumor responses in patients with various heavily treated cancers such as lung, prostate, or esophageal cancer. The study revealed a 32% response rate (95% CI: 24-41) with 38 responses (33 confirmed; 28%; 95% CI: 20-37) among 118 patients diagnosed with diverse solid tumors. These included small cell lung cancer (SCLC), squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), or endometrial cancer. The patients were administered DS-7300 doses ranging from 4.8 mg/kg to 16.0 mg/kg.
• In September 2022, Integral Molecular has granted CARTEXELL an exclusive license for a range of monoclonal antibodies (MAbs) aimed at aiding the development of CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs. This agreement allows CARTEXELL to leverage the CLND18.2 MAbs, acknowledged for their high specificity, strong affinity, and full humanization, to create CAR-T cell therapies directed at solid tumors such as gastric, lung, pancreatic, and esophageal cancers. Under the agreement terms, CARTEXELL assumes complete responsibility for all aspects of research, development, and commercial pursuits.
• In August 2022, BeiGene announced that the China National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) has granted approval for a supplemental biologics license application (sBLA) concerning tislelizumab. This application specifically addresses the utilization of tislelizumab alongside chemotherapy as an initial treatment for patients diagnosed with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
• In May 2022, Shanghai Junshi Biosciences Co., Ltd, announced that the China National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab used alongside paclitaxel and cisplatin. This clearance is granted for the initial treatment of patients dealing with unresectable locally advanced, recurrent, or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was submitted in July 2021 and marks the fifth approved indication for toripalimab in China. This decision is anticipated to bring significant benefits to Chinese patients managing advanced ESCC.


Esophageal Cancer Overview
Esophageal cancer emerges when malignant cells form within the esophagus, a lengthy tube connecting the throat to the stomach. Responsible for transporting ingested food to the stomach, the esophagus is a component of the upper digestive system. The primary types of esophageal cancer include squamous cell carcinoma and adenocarcinoma.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:
• CDR404: CDR-Life Inc
• AN-0025: Adlai Nortye Biopharma
• M1231: Merck KGaA
• Sotigalimab: Apexigen
• Amivantamab: Genmab
• Telomelysin: Oncolys BioPharma Inc
• Tiragolumab: Genentech
• S-588410: OncoTherapy Science, Inc. /Shionogi & Co., Ltd.
• CS1001: CStone Pharmaceuticals

Esophageal Cancer Route of Administration
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Esophageal Cancer Molecule Type
Esophageal Cancer Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment
• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage and Product Type
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer By Stage and Route of Administration
• Esophageal Cancer Assessment by Molecule Type
• Esophageal Cancer by Stage and Molecule Type

DelveInsight's Esophageal Cancer Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies at:
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Esophageal Cancer Therapeutics Market include:
Key companies developing therapies for Esophageal Cancer are - Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi, and others.

Esophageal Cancer Pipeline Analysis:
The Esophageal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Esophageal Cancer Pipeline Market Drivers
• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers
• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Esophageal Cancer Companies: , and others
• Key Esophageal Cancer Therapies: , and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Esophageal Cancer Report Introduction
2. Esophageal Cancer Executive Summary
3. Esophageal Cancer Overview
4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment
5. Esophageal Cancer Pipeline Therapeutics
6. Esophageal Cancer Late Stage Products (Phase II/III)
7. Esophageal Cancer Mid Stage Products (Phase II)
8. Esophageal Cancer Early Stage Products (Phase I)
9. Esophageal Cancer Preclinical Stage Products
10. Esophageal Cancer Therapeutics Assessment
11. Esophageal Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Esophageal Cancer Key Companies
14. Esophageal Cancer Key Products
15. Esophageal Cancer Unmet Needs
16 . Esophageal Cancer Market Drivers and Barriers
17. Esophageal Cancer Future Perspectives and Conclusion
18. Esophageal Cancer Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.